Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites

Abstract

Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.

Original language	English
Pages (from-to)	275-280
Number of pages	6
Journal	Journal of Perinatology
Volume	30
Issue number	4
DOIs	https://doi.org/10.1038/jp.2009.155
Publication status	Published - Apr 2010
Externally published	Yes

Keywords

Bronchopulmonary dysplasia
Nitrite
NO CLD trial

ASJC Scopus subject areas

Obstetrics and Gynaecology
Pediatrics, Perinatology, and Child Health

Access to Document

10.1038/jp.2009.155

Fingerprint Dive into the research topics of 'Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites'. Together they form a unique fingerprint.

Cite this

@article{7e5d3a641ceb4c95ab0b3c0643c7cc67,

title = "Inhaled nitric oxide in premature infants: Effect on tracheal aspirate and plasma nitric oxide metabolites",

abstract = "Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.",

keywords = "Bronchopulmonary dysplasia, Nitrite, NO CLD trial",

author = "Posencheg, {M. A.} and Gow, {A. J.} and Truog, {W. E.} and Ballard, {R. A.} and A. Cnaan and Golombek, {S. G.} and Ballard, {P. L.}",

year = "2010",

month = apr,

doi = "10.1038/jp.2009.155",

language = "English",

volume = "30",

pages = "275--280",

journal = "Journal of Perinatology",

issn = "0743-8346",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - Inhaled nitric oxide in premature infants

T2 - Effect on tracheal aspirate and plasma nitric oxide metabolites

AU - Posencheg, M. A.

AU - Gow, A. J.

AU - Truog, W. E.

AU - Ballard, R. A.

AU - Cnaan, A.

AU - Golombek, S. G.

AU - Ballard, P. L.

PY - 2010/4

Y1 - 2010/4

N2 - Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.

AB - Objective:Inhaled nitric oxide (iNO) is a potential new therapy for prevention of bronchopulmonary dysplasia and brain injury in premature infants. This study examined dose-related effects of iNO on NO metabolites as evidence of NO delivery.Study Design:A subset of 102 premature infants in the NO CLD trial, receiving 24 days of iNO (20 p.p.m. decreasing to 2 p.p.m.) or placebo, were analyzed. Tracheal aspirate (TA) and plasma samples collected at enrollment and at intervals during study gas were analyzed for NO metabolites.Result:iNO treatment increased NO metabolites in TA at 20 and 10 p.p.m. (1.7- to 2.3-fold vs control) and in plasma at 20, 10, and 5 p.p.m. (1.6- to 2.3-fold). In post hoc analysis, treated infants with lower metabolite levels at entry had an improved clinical outcome.Conclusion:iNO causes dose-related increases in NO metabolites in the circulation as well as lung fluid, as evidenced by TA analysis, showing NO delivery to these compartments.

KW - Bronchopulmonary dysplasia

KW - Nitrite

KW - NO CLD trial

UR - http://www.scopus.com/inward/record.url?scp=77950517036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950517036&partnerID=8YFLogxK

U2 - 10.1038/jp.2009.155

DO - 10.1038/jp.2009.155

M3 - Article

C2 - 19812581

AN - SCOPUS:77950517036

VL - 30

SP - 275

EP - 280

JO - Journal of Perinatology

JF - Journal of Perinatology

SN - 0743-8346

IS - 4